Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®
Oslo, Norway, 4 November 2016 Nordic Nanovector ASA (OSE: NANO) announces that the independent Safety Review Committee (SRC) for the ongoing Lymrit 37-01 clinical trial of Betalutin® in relapsed/refractory NHL, has recommended escalating the dose of Betalutin® in Arm 4 from 15 MBq/kg to 20 MBq/kg following pre-dosing with 100 mg/m2 lilotomab. Recruitment of 3 patients into Arm 4 to receive this new higher dosing regimen is now underway. The SRC also concluded that Arm 3 should be discontinued. The decision follows a review by the SRC of the available safety and dosimetry data from the